Skip to nav Skip to content
Farhad  Khimani

Farhad Khimani, MD

4.8 (29)

Specialty: Blood and Marrow Transplant and Cellular Immunotherapy

Program: Blood and Marrow Transplant and Cellular Immunotherapy

Language(s): English

  • Overview

    Cancer Focus:
    Hodgkin Lymphoma, Leukemia, Myelodysplastic Syndromes (MDS), Non-Hodgkin Lymphoma

    Dr. Khimani’s Clinical interest is specifically in Blood and Marrow transplantation. His area of focus is Lymphoma and Acute Leukemia.  He routinely takes care of patients with Hodgkin’s lymphoma, Non-Hodgkin’s lymphoma, Acute Myeloid leukemia, acute lymphoblastic leukemia and myelodysplastic syndrome etc. who require autologous or allogeneic hematopoietic stem cell transplantation as a curative treatment option for their malignancy.

    Education & Training

    Board Certification:

    • Internal Medicine - Hematology
    • Internal Medicine - Medical Oncology

    Fellowship:

    • West Virginia University - Hematology/Oncology
    • Moffitt Cancer Center - Blood and Marrow Transplantation

    Residency:

    • West Virginia University - Internal Medicine

    Medical School:

    • Aga Khan University Medical College - MD
  • Participating Trials

    Clinical Trial 22699
    A Phase II Study of Reduced Dose Post Transplantation Cyclophosphamide as GvHD Prophylaxis in Adult Patients with Hematologic Malignancies Receiving HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation
    Condition: Malignant Hematology
    Intervention: Cellcept (Mycophenolate Mofetil); FK506 (Tacrolimus); Mycophenolate Mofetil (); Tacrolimus (); cyclophosphamide (); cytoxan (cyclophosphamide)
    Status: Open

    If you believe you are eligible for one of these trials or studies, please call
    813-745-6100 or toll-free 1-800-679-0775.

  • Publications

    • Moustafa MA, Ramdial JL, Tsalatsanis A, Khimani F, Dholaria B, Bojanini L, Brooks T, Zain J, Bennani NN, Braunstein Z, Brammer JE, Beitinjaneh A, Jagadeesh D, Weng WK, Kumar A, Kharfan-Dabaja MA, Ahmed S, Murthy HS. A US Multicenter Collaborative Study on Outcomes of Hematopoietic Cell Transplantation in Hepatosplenic T-Cell Lymphoma. Transplant Cell Ther. 2024 May.30(5):516.e1-516.e10. Pubmedid: 38431075.
    • Zhang Y, Rose A, Khadka S, Cao B, Eatrides J, Saeed H, Shah BD, Chavez J, Bello C, Lazaryan A, Khimani F, Ibarz JP, Liu HD, Locke FL, Jain MD, Zhang L, Kharfan-Dabaja MA, Kim J, Ayala E, Nishihori T, Sokol L. Autologous hematopoietic cell transplantation consolidation for first response is associated with longer survival among patients with nodal peripheral T-cell lymphoma. Transplant Cell Ther. 2024 May. Pubmedid: 38740140.
    • Faramand RG, Lee SB, Jain MD, Cao B, Wang X, Rejeski K, Subklewe M, Fahrmann JF, Saini NY, Hanash SM, Kang YP, Chang D, Rodriguez PC, Dean EA, Nishihori T, Shah BD, Lazaryan A, Chavez J, Khimani F, Pinilla-Ibarz JA, Dam M, Reid KM, Corallo SA, Menges M, Hidalgo Vargas M, Mandula JK, Holliday BA, Bachmeier CA, Speth K, Song Q, Mattie M, Locke FL, Davila ML. Baseline Serum Inflammatory Proteins Predict Poor CAR T Outcomes in Diffuse Large B-cell Lymphoma. Blood Cancer Discov. 2024 Mar.5(2):106-113. Pubmedid: 38194367. Pmcid: PMC10905320.
    • Caprice T, Fan W, Kim J, Faramand R, Mishra A, Perez L, Khimani F, Lazar-Yan A, Ochoa-Bayona JL, Liu H, Jain MD, Nieder M, Anasetti C, Nishihori T, Pidala JA, Bejanyan N, Elmariah H. Mismatched donor allogeneic hematopoietic cell transplantation with post-transplant cyclophosphamide achieves comparable outcomes between racially and ethnically diverse patient populations. Am J Hematol. 2024 Jun.99(6):1196-1200. Pubmedid: 38546371.
    • Elmariah H, Otoukesh S, Kumar A, Ali H, Arslan S, Shouse G, Pourhassan H, Nishihori T, Faramand R, Mishra A, Khimani F, Fernandez H, Lazaryan A, Nieder M, Perez L, Liu H, Nakamura R, Pidala J, Marcucci G, Forman SJ, Anasetti C, Locke F, Bejanyan N, Al Malki MM. Sirolimus Is an Acceptable Alternative to Tacrolimus for Graft-versus-Host Disease Prophylaxis after Haploidentical Peripheral Blood Stem Cell Transplantation with Post-Transplantation Cyclophosphamide. Transplant Cell Ther. 2024 Feb.30(2):229.e1-229.e11. Pubmedid: 37952648.
    • Roman Diaz JL, Vazquez Martinez M, Khimani F. New Approaches for the Treatment of AML beyond the 7+3 Regimen: Current Concepts and New Approaches. Cancers (Basel). 2024 Feb.16(3). Pubmedid: 38339429. Pmcid: PMC10854755.
    • Ionescu F, David JC, Ravichandran A, Sallman DA, Sweet K, Komrokji RS, Chan O, Kuykendall A, Padron E, Faramand R, Bejanyan N, Khimani F, Elmariah H, Pidala J, Mishra A, Perez L, Nishihori T, Lancet JE. Hypomethylating Agents and Venetoclax for Acute Myeloid Leukemia Relapsed After Hematopoietic Stem Cell Transplant. Clin Lymphoma Myeloma Leuk. 2024 Feb. Pubmedid: 38429222.
    • Sauls R, Crowder SL, James C, Khimani F, Stern M. Quality of life in the digital age: young adult hematopoietic stem cell transplantation patients and healthcare providers' views of telehealth. Support Care Cancer. 2024 Apr.32(4):270. Pubmedid: 38578444.
    • Gonzalez R, Gaskill E, Padilla M, Pidala J, Lazaryan A, Perez L, Khimani F, Faramand R. Belumosudil Impacts Immunosuppression Pharmacokinetics in Patients with Chronic Graft-versus-Host Disease. Transplant Cell Ther. 2023 Sep.29(9):577.e1-577.e9. Pubmedid: 37355201.
    • Ibrahim U, Bassil C, Chavez JC, Khimani F, Jain MD, Locke FL, Lazaryan A, Osman K. CAR T Cell Therapy for Post-Transplant Lymphoproliferative Disorder After Solid Organ Transplantation: A Safe and Feasible Therapy for an Orphan Disease. Clin Lymphoma Myeloma Leuk. 2023 Oct.23(10):772-778. Pubmedid: 37263876.
    • Shaw BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, Khimani F, Shaffer BC, Shah NN, Mussetter A, Tang XY, McCarty JM, Alavi A, Farhadfar N, Jamieson K, Hardy NM, Choe H, Ambinder RF, Anasetti C, Perales MA, Spellman SR, Howard A, Komanduri KV, Luznik L, Norkin M, Pidala JA, Ratanatharathorn V, Confer DL, Devine SM, Horowitz MM, Bolaños-Meade J. Three-Year Outcomes in Recipients of Mismatched Unrelated Bone Marrow Donor Transplants Using Post-Transplantation Cyclophosphamide: Follow-Up from a National Marrow Donor Program-Sponsored Prospective Clinical Trial. Transplant Cell Ther. 2023 Mar.29(3):208.e1-208.e6. Pubmedid: 36584941. Pmcid: PMC9992261.
    • Dong N, Lopes-Garcia LR, Viñal D, Bachmeier C, Shah BD, Nishihori T, Khimani F, Davila ML, Lazaryan A, Pinilla-Ibarz J, Locke FL, Jain MD, Chavez JC. Outcomes of CD19-Directed Chimeric Antigen Receptor T Cell Therapy for Transformed Nonfollicular Lymphoma. Transplant Cell Ther. 2023 Jun.29(6):349.e1-349.e8. Pubmedid: 36878427.
    • Keit E, Liveringhouse C, Figura N, Weygand J, Sandoval ML, Garcia G, Peters J, Nieder M, Faramand R, Khimani F, Kim S, Robinson TJ, Johnstone PAS, Penagaricano J, Latifi K. Feasibility and Toxicity of Full-Body Volumetric Modulated Arc Therapy Technique for High-Dose Total Body Irradiation. Technol Cancer Res Treat. 2023 Jan.22. Pubmedid: 37287260. Pmcid: PMC10272663.
    • Sauls R, Buro AW, Montgomery L, Stern M, Khimani F, Crowder SL. Nutritional status and body mass index before hematopoietic stem cell transplantation (HSCT) and associated outcomes: a rapid review. Support Care Cancer. 2023 Dec.32(1):50. Pubmedid: 38129689.
    • Lee DH, Kumar A, Mohammed T, Peres LC, Alsina M, Bachmeier CA, Blue B, Brayer J, Chandrasekhar S, Grajales-Cruz AF, De Avila G, Elmariah H, Faramand RG, Freeman CL, Jain MD, Khadka S, Khimani F, Liu H, Nishihori T, Oswald LB, Castaneda Puglianini OA, Shain KH, Smith E, Baz RC, Locke FL, Oliveira GH, Alomar M, Hansen DK. Cardiac events after standard of care idecabtagene vicleucel for relapsed and refractory multiple myeloma. Blood Adv. 2023 Aug.7(16):4247-4257. Pubmedid: 37307173. Pmcid: PMC10424134.
    • Lee DH, Chandrasekhar S, Jain MD, Mhaskar R, Reid K, Lee SB, Corallo S, Hidalgo-Vargas MJ, Kumar A, Chavez J, Shah B, Lazaryan A, Khimani F, Nishihori T, Bachmeier C, Faramand R, Fradley MG, Jeong D, Oliveira GH, Locke FL, Davila ML, Alomar M. Cardiac and inflammatory biomarker differences in adverse cardiac events after chimeric antigen receptor T-Cell therapy: an exploratory study. Cardiooncology. 2023 Apr.9(1):18. Pubmedid: 37005652. Pmcid: PMC10067156.
    • Shadman M, Pasquini MC, Ahn KW, Chen Y, Turtle CJ, Hematti P, Cohen JB, Khimani F, Ganguly S, Merryman RW, Yared JA, Locke FL, Ahmed N, Munshi P, Beitinjaneh A, Reagan P, Herrera AF, Sauter CS, Kharfan-Dabaja MA, Hamadani M. Autologous transplant vs chimeric antigen receptor T-cell therapy for relapsed DLBCL in partial remission. Blood. 2022 Mar.139(9):1330-1339. Pubmedid: 34570879. Pmcid: PMC8900276.
    • Crowder SL, Sauls R, Redwine L, Nieder M, Albanyan O, Yasin H, Khimani F, Stern M. Mindfulness in Adolescent and Young Adult (AYA) Patients Undergoing Hematopoietic Stem Cell Transplantation (HSCT): A Qualitative Study. Cancers (Basel). 2022 Jun.14(11). Pubmedid: 35681740. Pmcid: PMC9179916.
    • Perez A, Johnson G, Patel K, Arciola B, Wood A, Bachmeier CA, Chavez JC, Shah BD, Khimani F, Nishihori T, Lazaryan A, Davila ML, Mhaskar R, Locke FL, Gaballa S, Jain MD. Primary progression during frontline CIT associates with decreased efficacy of subsequent CD19 CAR T-cell therapy in LBCL. Blood Adv. 2022 Jul.6(13):3970-3973. Pubmedid: 35816359. Pmcid: PMC9278282.
    • Lazaryan A, Lee SJ, Arora M, Kim J, Betts BC, Khimani F, Nishihori T, Bejanyan N, Liu H, Kharfan-Dabaja MA, Locke FL, Gonzalez R, Jain MD, Davila ML, Perez LE, Mishra A, Perez Perez A, Balke K, Ayala E, Ochoa L, Castaneda Puglianini O, Faramand RG, Alsina M, Elmariah H, Nieder M, Fernandez H, Anasetti C, Pidala J. A phase 2 multicenter trial of ofatumumab and prednisone as initial therapy for chronic graft-versus-host disease. Blood Adv. 2022 Jan.6(1):259-269. Pubmedid: 34649279. Pmcid: PMC8753213.
    • Menghrajani K, Gomez-Arteaga A, Madero-Marroquin R, Zhang MJ, Bo-Subait K, Sanchez J, Wang HL, Aljurf M, Assal A, Bacher U, Badawy SM, Bejanyan N, Bhatt VR, Bredeson CN, Byrne M, Castillo P, Cerny J, Chhabra S, Ciurea SO, DeFilipp Z, Farhadfar N, Gadalla SM, Gale RP, Ganguly S, Gowda L, Grunwald MR, Hashmi S, Hildebrandt GC, Kanakry CG, Kansagra A, Khimani F, Krem M, Lazarus HM, Liu H, Martino R, Michelis FV, Nathan S, Nishihori T, Olsson RF, Reshef R, Rizzieri D, Rowe JM, Savani BN, Seo S, Sharma A, Solh M, Ustun C, Verdonck LF, Hourigan CS, Sandmaier BM, Litzow MR, Kebriaei P, Weisdorf DJ, Zhang Y, Tallman MS, Saber W. Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML. Blood Adv. 2022 Jan.6(3):828-847. Pubmedid: 34551064. Pmcid: PMC8945306.
    • Hamadani M, Ngoya M, Sureda A, Bashir Q, Litovich CA, Finel H, Chen Y, Boumendil A, Zain J, Castagna L, Cashen AF, Blaise D, Shadman M, Pastano R, Khimani F, Arat M, Dietrich S, Schmitz N, Glass B, Kharfan-Dabaja MA, Corradini P, Sauter CS, Montoto S, Kwon M, Herrera AF, Dreger P. Outcome of allogeneic transplantation for mature T-cell lymphomas: impact of donor source and disease characteristics. Blood Adv. 2022 Feb.6(3):920-930. Pubmedid: 34861680. Pmcid: PMC8945300.
    • Wood AC, Perez AP, Arciola B, Patel K, Johnson G, DiMaggio E, Bachmeier CA, Reid K, Carallo S, Vargas MH, Faramand R, Chavez JC, Shah B, Gaballa S, Khimani F, Elmariah H, Nishihori T, Lazaryan A, Freeman C, Davila ML, Locke FL, Mhaskar R, Bassil C, Jain MD. Outcomes of CD19-Targeted Chimeric Antigen Receptor T Cell Therapy for Patients with Reduced Renal Function Including Dialysis. Transplant Cell Ther. 2022 Dec.28(12):829.e1-829.e8. Pubmedid: 36174934. Pmcid: PMC9791940.
    • Logue JM, Peres LC, Hashmi H, Colin-Leitzinger C, Shrewsbury AM, Hosoya H, Gonzalez R, Copponex C, Kottra KH, Hovanky V, Sahaf B, Patil S, Lazaryan A, Jain MD, Baluch A, Klinkova O, Bejanyan N, Faramand RG, Elmariah H, Khimani F, Davila ML, Mishra A, Blue B, Grajales-Cruz AF, Castaneda Puglianini O, Liu H, Nishihori T, Freeman CL, Brayer J, Shain KH, Baz R, Locke FL, Alsina M, Sidana S, Hansen DK. Early cytopenias and infections after standard of care idecabtagene vicleucel in relapsed or refractory multiple myeloma. Blood Adv. 2022 Dec.6(24):6109-6119. Pubmedid: 35939783. Pmcid: PMC9768247.
    • Savani M, Ahn KW, Chen Y, Ahmed S, Cashen AF, Shadman M, Modi D, Khimani F, Cutler CS, Zain J, Brammer JE, Rezvani AR, Fenske TS, Sauter CS, Kharfan-Dabaja MA, Herrera AF, Hamadani M. Impact of conditioning regimen intensity on the outcomes of peripheral T-cell lymphoma, anaplastic large cell lymphoma and angioimmunoblastic T-cell lymphoma patients undergoing allogeneic transplant. Brit J Haematol. 2022 Apr.197(2):212-222. Pubmedid: 35106754. Pmcid: PMC9018546.
    • Mirza AS, Tandon A, Jenneman D, Cao S, Brimer T, Kumar A, Kidd M, Khimani F, Faramand R, Mishra A, Liu H, Nishihori T, Perez L, Lazaryan A, Bejanyan N, Nieder M, Pidala J, Elmariah H. Outcomes Following Intolerance to Tacrolimus/Sirolimus Graft-versus-Host Disease Prophylaxis for Allogeneic Hematopoietic Cell Transplantation. Transplant Cell Ther. 2022 Apr.28(4):185.e1-185.e7. Pubmedid: 35017119.
    • Lozano-Chinga M, Diaz-Cabrera N, Khimani F, Chen K, Bohnsack J, Walter JE, Tabatabaian F, Afify Z. Lymphoma in Partial DiGeorge Syndrome: Report of 2 Cases. J Pediat Hematol Onc. 2022 Apr.44(3):e819-e822. Pubmedid: 34966099.
    • Cortes A, Perez A, Bachmeier C, Mhaskar R, Chavez JC, Shah B, Nishihori T, Khimani F, Lazaryan A, Davila ML, Locke FL, Jain MD. Outcomes of CD19 Chimeric Antigen Receptor T Cell Therapy in Patients with Gastrointestinal Tract Involvement of Large B Cell Lymphoma. Transplant Cell Ther. 2021 Sep.27(9):768.e1-768.e6. Pubmedid: 34077811. Pmcid: PMC8403629.
    • Khimani F, Ranspach P, Elmariah H, Kim J, Whiting J, Nishihori T, Locke FL, Perez Perez A, Dean E, Mishra A, Perez L, Lazaryan A, Jain MD, Nieder M, Liu H, Faramand R, Hansen D, Alsina M, Ochoa L, Davila M, Anasetti C, Pidala J, Bejanyan N. Increased Infections and Delayed CD4+ T Cell but Faster B Cell Immune Reconstitution after Post-Transplantation Cyclophosphamide Compared to Conventional GVHD Prophylaxis in Allogeneic Transplantation. Transplant Cell Ther. 2021 Nov.27(11):940-948. Pubmedid: 34329754.
    • Abedin S, Rashid N, Schroeder M, Romee R, Nauffal M, Alhaj Moustafa M, Kharfan-Dabaja MA, Palmer J, Hogan W, Hefazi M, Larson S, Holtan S, DeFilipp Z, Jayani R, Dholaria B, Pidala J, Khimani F, Grunwald MR, Butler C, Hamadani M. Ruxolitinib resistance or intolerance in steroid-refractory acute graft-versus-host disease - a real-world outcomes analysis. Brit J Haematol. 2021 Nov.195(3):429-432. Pubmedid: 34254289. Pmcid: PMC9293486.
    • Pidala J, Walton K, Elmariah H, Kim J, Mishra A, Bejanyan N, Nishihori T, Khimani F, Perez L, Faramand RG, Davila ML, Nieder ML, Sagatys EM, Holtan SG, Lawrence NJ, Lawrence HR, Blazar BR, Anasetti C, Sebti SM, Betts BC. Pacritinib Combined with Sirolimus and Low-Dose Tacrolimus for GVHD Prevention after Allogeneic Hematopoietic Cell Transplantation: Preclinical and Phase I Trial Results. Clin Cancer Res. 2021 May.27(10):2712-2722. Pubmedid: 33753457. Pmcid: PMC8127396.
    • Hoogland AI, Jayani RV, Collier A, Irizarry-Arroyo N, Rodriguez Y, Jain MD, Booth-Jones M, Hyland KA, James BW, Barata A, Bachmeier CA, Chavez JC, Khimani F, Krivenko GS, Lazaryan A, Liu HD, Nishihori T, Pinilla-Ibarz J, Shah BD, Abidi M, Locke FL, Jim HSL. Acute patient-reported outcomes in B-cell malignancies treated with axicabtagene ciloleucel. Cancer Med. 2021 Mar.10(6):1936-1943. Pubmedid: 33641257. Pmcid: PMC7957158.
    • Bejanyan N, Pidala JA, Wang X, Thapa R, Nishihori T, Elmariah H, Lazaryan A, Khimani F, Davila ML, Mishra A, Faramand R, Jain MD, Ochoa L, Perez LE, Liu H, Alsina M, Kharfan-Dabaja MA, Fernandez H, Nieder ML, Locke FL, Anasetti C, Ayala E. A phase 2 trial of GVHD prophylaxis with PTCy, sirolimus, and MMF after peripheral blood haploidentical transplantation. Blood Adv. 2021 Mar.5(5):1154-1163. Pubmedid: 33635333. Pmcid: PMC7948297.
    • Hansen DK, Kim J, Thompson Z, Hussaini M, Nishihori T, Ahmad A, Elmariah H, Faramand R, Mishra A, Davila ML, Khimani F, Lazaryan A, Sallman D, Liu H, Perez LE, Fernandez H, Nieder ML, Lancet JE, Pidala JA, Anasetti C, Bejanyan N. ELN 2017 Genetic Risk Stratification Predicts Survival of Acute Myeloid Leukemia Patients Receiving Allogeneic Hematopoietic Stem Cell Transplantation. Transplant Cell Ther. 2021 Mar.27(3):256.e1-256.e7. Pubmedid: 33781526. Pmcid: PMC8711732.
    • Mirza AS, Kumar A, Hashmi H, Garcia F, Logothetis CN, Darwin A, Faramand R, Reid K, Bachmeier C, Chavez JC, Shah B, Pinilla-Ibarz J, Khimani F, Lazaryan A, Liu H, Davila ML, Nishihori T, Locke FL, Jain MD. Incidence and Management of Effusions Before and After CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy in Large B Cell Lymphoma. Transplant Cell Ther. 2021 Mar.27(3):242.e1-242.e6. Pubmedid: 33781520.
    • Shaw BE, Jimenez-Jimenez AM, Burns LJ, Logan BR, Khimani F, Shaffer BC, Shah NN, Mussetter A, Tang XY, McCarty JM, Alavi A, Farhadfar N, Jamieson K, Hardy NM, Choe H, Ambinder RF, Anasetti C, Perales MA, Spellman SR, Howard A, Komanduri KV, Luznik L, Norkin M, Pidala JA, Ratanatharathorn V, Confer DL, Devine SM, Horowitz MM, Bolaños-Meade J. National Marrow Donor Program-Sponsored Multicenter, Phase II Trial of HLA-Mismatched Unrelated Donor Bone Marrow Transplantation Using Post-Transplant Cyclophosphamide. J Clin Oncol. 2021 Jun.39(18):1971-1982. Pubmedid: 33905264. Pmcid: PMC8260905.
    • Scordo M, Wang TP, Ahn KW, Chen Y, Ahmed S, Awan FT, Beitinjaneh A, Chen A, Chow VA, Dholaria B, Epperla N, Farooq U, Ghosh N, Grover N, Hamad N, Hildebrandt GC, Holmberg L, Hong S, Inwards DJ, Jimenez-Jimenez A, Karmali R, Kenkre VP, Khimani F, Klyuchnikov E, Krem MM, Munshi PN, Nieto Y, Prestidge T, Ramakrishnan Geethakumari P, Rezvani AR, Riedell PA, Seo S, Shah NN, Solh M, Yared JA, Kharfan-Dabaja MA, Herrera A, Hamadani M, Sauter CS. Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant. JAMA Oncol. 2021 Jul.7(7):993-1003. Pubmedid: 33956047. Pmcid: PMC8283558.
    • Khimani F, Dutta M, Faramand R, Nishihori T, Perez AP, Dean E, Nieder M, Perez L, Mishra A, Elmariah H, Davila M, Ochoa L, Alsina M, Lazaryan A, Bejanyan N, Hansen D, Jain M, Locke F, Liu H, Pidala J, Shah B, Mhaskar R. Impact of Total Body Irradiation-Based Myeloablative Conditioning Regimens in Patients with Acute Lymphoblastic Leukemia Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: Systematic Review and Meta-Analysis. Transplant Cell Ther. 2021 Jul.27(7):620.e1-620.e9. Pubmedid: 33798768.
    • Perez L, Fernandez H, Kharfan-Dabaja M, Khimani F, Betts B, Mishra A, Ayala E, Locke FL, Ochoa-Bayona L, Nieder M, Pidala J, Achille A, Powers J, Sahakian E, Thapa R, Wang X, Anasetti C. A phase 2 trial of the histone deacetylase inhibitor panobinostat for graft-versus-host disease prevention. Blood Adv. 2021 Jul.5(13):2740-2750. Pubmedid: 34242388. Pmcid: PMC8288668.
    • Elmariah H, Naqvi SMH, Kim J, Nishihori T, Mishra A, Perez L, Faramand R, Lazaryan A, Liu HD, Khimani F, Nieder M, Anasetti C, Pidala J, Bejanyan N. Impact of infused CD34+ stem cell dosing for allogeneic peripheral blood stem cell transplantation with post-transplant cyclophosphamide. Bone Marrow Transplant. 2021 Jul.56(7):1683-1690. Pubmedid: 33658647.
    • Figura NB, Robinson TJ, Sim AJ, Wang X, Cao B, Chavez JC, Shah BD, Khimani F, Lazaryan A, Davila M, Bachmeier C, Nishihori T, Liu HD, Kim S, Locke FL, Jain MD. Patterns and Predictors of Failure in Recurrent or Refractory Large B-Cell Lymphomas After Chimeric Antigen Receptor T-Cell Therapy. Int J Radiat Oncol Biol Phys. 2021 Dec.111(5):1145-1154. Pubmedid: 34242714. Pmcid: PMC9791939.
    • Logue JM, Zucchetti E, Bachmeier CA, Krivenko GS, Larson V, Ninh D, Grillo G, Cao B, Kim J, Chavez JC, Baluch A, Khimani F, Lazaryan A, Nishihori T, Liu HD, Pinilla-Ibarz J, Shah BD, Faramand R, Coghill AE, Davila ML, Dholaria BR, Jain MD, Locke FL. Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma. Haematologica. 2021 Apr.106(4):978-986. Pubmedid: 32327504. Pmcid: PMC8017820.
    • Faramand R, Jain M, Staedtke V, Kotani H, Bai R, Reid K, Lee SB, Spitler K, Wang X, Cao B, Pinilla J, Lazaryan A, Khimani F, Shah B, Chavez JC, Nishihori T, Mishra A, Mullinax J, Gonzalez R, Hussaini M, Dam M, Brandjes BD, Bachmeier CA, Anasetti C, Locke FL, Davila ML. Tumor Microenvironment Composition and Severe Cytokine Release Syndrome (CRS) Influence Toxicity in Patients with Large B-Cell Lymphoma Treated with Axicabtagene Ciloleucel. Clin Cancer Res. 2020 Sep.26(18):4823-4831. Pubmedid: 32669372. Pmcid: PMC7501265.
    • Hashmi H, Mirza AS, Darwin A, Logothetis C, Garcia F, Kommalapati A, Mhaskar RS, Bachmeier C, Chavez JC, Shah B, Pinilla-Ibarz J, Khimani F, Lazaryan A, Liu H, Davila ML, Locke FL, Nishihori T, Jain MD. Venous thromboembolism associated with CD19-directed CAR T-cell therapy in large B-cell lymphoma. Blood Adv. 2020 Sep.4(17):4086-4090. Pubmedid: 32877523. Pmcid: PMC7479945.
    • Dean EA, Mhaskar RS, Lu H, Mousa MS, Krivenko GS, Lazaryan A, Bachmeier CA, Chavez JC, Nishihori T, Davila ML, Khimani F, Liu HD, Pinilla-Ibarz J, Shah BD, Jain MD, Balagurunathan Y, Locke FL. High metabolic tumor volume is associated with decreased efficacy of axicabtagene ciloleucel in large B-cell lymphoma. Blood Adv. 2020 Jul.4(14):3268-3276. Pubmedid: 32702097. Pmcid: PMC7391155.
    • DiMaggio E, Zhou JM, Caddell R, Tombleson R, Perkins J, Anasetti C, Khimani F, Pidala J, Nishihori T, Perez L, Betts B, Fernandez HF, Mishra A. Reduced-intensity fludarabine/melphalan confers similar survival to busulfan/fludarabine myeloablative regimens for patients with acute myeloid leukemia and myelodysplasia. Leuk Lymphoma. 2020 Jul.61(7):1678-1687. Pubmedid: 32133897. Pmcid: PMC7771324.
    • Epperla N, Ahn KW, Litovich C, Ahmed S, Battiwalla M, Cohen JB, Dahi P, Farhadfar N, Farooq U, Freytes CO, Ghosh N, Haverkos B, Herrera A, Hertzberg M, Hildebrandt G, Inwards D, Kharfan-Dabaja MA, Khimani F, Lazarus H, Lazaryan A, Lekakis L, Murthy H, Nathan S, Nishihori T, Pawarode A, Prestidge T, Ramakrishnan P, Rezvani AR, Romee R, Shah NN, Sureda A, Fenske TS, Hamadani M. Allogeneic hematopoietic cell transplantation provides effective salvage despite refractory disease or failed prior autologous transplant in angioimmunoblastic T-cell lymphoma: a CIBMTR analysis. J Hematol Oncol. 2019 Jan.12(1):6. Pubmedid: 30630534. Pmcid: PMC6329157.
    • Khimani F, McDonald GB, Shulman HM, Betts B, Locke F, Fernandez H, Anasetti C, Pidala J. Hepatic veno-occlusive disease following sirolimus-based immune suppression. Bone Marrow Transplant. 2019 Jan.54(1):85-89. Pubmedid: 29895929.
    • Sim AJ, Jain MD, Figura N, Chavez JC, Shah BD, Khimani F, Lazarayan A, Krivenko G, Davila ML, Liu HD, Falchook AD, Dahiya S, Rapoport AP, Kim SU, Locke FL, Robinson TJ. Radiation Therapy as a Bridging Strategy for CAR T Cell Therapy With Axicabtagene Ciloleucel in Diffuse Large B-Cell Lymphoma. Int J Radiat Oncol Biol Phys. 2019 Dec.105(5):1012-1021. Pubmedid: 31175906. Pmcid: PMC6872916.
    • Pidala J, Beato F, Kim J, Betts B, Jim H, Sagatys E, Levine JE, Ferrara JL, Ozbek U, Ayala E, Davila M, Fernandez HF, Field T, Kharfan-Dabaja MA, Khaira D, Khimani F, Locke FL, Mishra A, Nieder M, Nishihori T, Perez L, Riches M, Anasetti C. IL-12/IL-23p40 neutralization blocks Th1/Th17 response after allogeneic hematopoietic cell transplantation. Haematologica. 2018 Mar.103(3):531-539. Pubmedid: 29242294. Pmcid: PMC5830373.
    • Kharfan-Dabaja MA, Kumar A, Stingo FE, Khimani F, Hussaini M, Ayala E, Nishihori T, Shah B, Locke FL, Pinilla-Ibarz J, Chavez JC. Allogeneic Hematopoietic Cell Transplantation for Richter Syndrome: A Single-Center Experience. Clin Lymphoma Myeloma Leuk. 2018 Jan.18(1):e35-e39. Pubmedid: 29126867. Pmcid: PMC6716154.
    • Murthy HS, Sheets K, Kumar A, Nishihori T, Mina A, Chavez JC, Ayala E, Field T, Mathews J, Locke F, Perez L, Betts BC, Khimani F, Miladinovic B, Tsalatsanis A, Ochoa-Bayona JL, Alsina M, Fernandez H, Pidala J, Anasetti C, Kharfan-Dabaja MA. Hypoalbuminemia at Day +90 Is Associated with Inferior Nonrelapse Mortality and Overall Survival in Allogeneic Hematopoietic Cell Transplantation Recipients: A Confirmatory Study. Biol Blood Marrow Tr. 2018 Feb.24(2):400-405. Pubmedid: 29032266.
    • Betts BC, Pidala J, Kim J, Mishra A, Nishihori T, Perez L, Ochoa-Bayona JL, Khimani F, Walton K, Bookout R, Nieder M, Khaira DK, Davila M, Alsina M, Field T, Ayala E, Locke FL, Riches M, Kharfan-Dabaja M, Fernandez H, Anasetti C. IL-2 promotes early Treg reconstitution after allogeneic hematopoietic cell transplantation. Haematologica. 2017 May.102(5):948-957. Pubmedid: 28104702. Pmcid: PMC5477614.
    • Khimani F, Kim J, Chen L, Dean E, Rizk V, Betts B, Nishihori T, Locke F, Mishra A, Perez L, Ayala E, Kharfan-Dabaja M, Nieder M, Fernandez H, Anasetti C, Pidala J. Predictors of overall survival among patients treated with sirolimus/tacrolimus vs methotrexate/tacrolimus for GvHD prevention. Bone Marrow Transplant. 2017 Jul.52(7):1003-1009. Pubmedid: 28368376. Pmcid: PMC7771296.
    • Khimani F, Jeong DK, Miladinovic B, Nishihori T, Ayala E, Locke F, Mishra A, Chavez J, Shah B, Gage K, Kharfan-Dabaja MA. Nonfluorodeoxyglucose-Avid Persistent Splenomegaly at Time of Transplantation Delays Neutrophil and Platelets Engraftment without Affecting Survival in Patients with Lymphomas Undergoing Allogeneic Hematopoietic Cell Transplantation. Biol Blood Marrow Tr. 2016 Dec.22(12):2201-2207. Pubmedid: 27660169.
    • Khimani F, Curley B, Almubarak M. Survey of Patients Referred to a University Cancer Center for Benign Hematology: Quality Measures and Patient Understanding. J Oncol Pract. 2015 Jan.11(1):26-29. Pubmedid: 25406129.
    • Khimani F, Hoban C, Williams V, Mavromatis B, Auber ML, Abraham J, Higa GM. Efficacy of solubilized vemurafenib administered via nasogastric tube. Future Oncol. 2014 Feb.10(2):165-170. Pubmedid: 24490602.
    • Palla AR, Khimani F, Craig MD. Warm Autoimmune Hemolytic Anemia with a Direct Antiglobulin Test Positive for C3 and Negative for IgG: A Case Study and Analytical Literature Review of Incidence and Severity. Clin Med Insights Case Rep. 2013 May.6:57-60. Pubmedid: 23645992. Pmcid: PMC3623608.
    • Kamal A, Khimani F, Raza R, Zafar S, Bandeali S, Jan S. Characteristics of TIA and its management in a tertiary care hospital in Pakistan. BMC Res Notes. 2008 Aug.1:73. Pubmedid: 18755043. Pmcid: PMC2546420.
    • Majeed K, Mahmud H, Khawaja HR, Mansoor S, Masood S, Khimani F. Complementary and Alternative Medicine: Perceptions of Medical Students from Pakistan. Med Educ Online. 2007 Dec.12(1):4469. Pubmedid: 28253096.
  • Patient Comments

    Overall Satisfaction

    4.8

    29 patients rated this provider

    The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. Responses are measured on a scale of 1 to 5 with 5 being the best score.

    Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

    Learn more about our patient satisfaction survey

     

    Comments

    Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

    We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

    Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

    Learn more about our patient comments

    Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

    • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
    • He or she may be a researcher or other type of provider that does not see patients.
    • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.

    Learn more about our patient satisfaction survey, ratings and comments

Find a Doctor